IDEX

IDEX Corporation Q4 Earnings Call Highlights: HST Segment Leads the Way with Record Orders and Margin Expansion

Argus Research upgrades Buy on IDEX to $240 with a new Hold rating.

IDEX 15min chart shows KDJ Death Cross, bearish Marubozu pattern.

IDEX Corporation: A Bullish Outlook Amid Attractive Sector Valuations

DA Davidson Raises PT to $195, Maintains Neutral on IDEX Stock

Catalyst<ul> <li>Most analysts rate IEX Buy or Strong Buy, showing broad institutional optimism.</li> <li>Fund flows show positive net inflow across all order size buckets, indicating growing institutional interest.</li></ul>Risk<ul> <li>Technical indicators show that the market is in a weak state, and we need to pay attention to the risk of decline.</li> <li>Bearish signals are obviously dominant (4 bearish vs 0 bullish), suggesting potential downward momentum.</li></ul>

Key Factors

IDEX Corporation reported Q4 earnings with Health & Science Technologies segment orders at a record $493 million, driving organic revenue growth and margin expansion. IDEX’s Q4 2025 earnings beat estimates, with revenue of $899.1 million and EPS of $2.10, exceeding analyst forecasts by 2.2% and 2.9%, respectively. IDEX Corporation raised full-year 2026 guidance for adjusted EBITDA margin to 26.5–27% and adjusted EPS to $8.15–$8.35, reflecting cautious optimism. IDEX returned $617 million in free cash flow to shareholders via dividends, buybacks, and reduced leverage during Q4 2025. IDEX’s Health & Science Technologies segment orders surged 34% in Q4, driven by AI and semiconductor sector momentum.

IEX News